炎症性肠病
PLGA公司
透明质酸
纳米颗粒
炎症
药理学
乙醇酸
壳聚糖
化学
材料科学
医学
乳酸
纳米技术
免疫学
生物化学
内科学
生物
疾病
遗传学
细菌
解剖
作者
Junshan Wang,Min Yao,Jiafeng Zou,Wenxing Ding,Mingyue Sun,Ying Zhuge,Feng Gao
出处
期刊:Nanomaterials
[Multidisciplinary Digital Publishing Institute]
日期:2023-10-20
卷期号:13 (20): 2797-2797
被引量:3
摘要
Though the anti-miR-301a (anti-miR) is a promising treatment strategy for inflammatory bowel disease (IBD), the degradability and the poor targeting of the intestine are a familiar issue. This study aimed to develop a multifunctional oral nanoparticle delivery system loaded with anti-miR for improving the targeting ability and the therapeutic efficacy. The HA-CS/ES100/PLGA nanoparticles (HCeP NPs) were prepared using poly (lactic-co-glycolic acid) copolymer (PLGA), enteric material Eudragit®S100 (ES100), chitosan (CS), and hyaluronic acid (HA). The toxicity of nanoparticles was investigated via the Cell Counting Kit-8, and the cellular uptake and inflammatory factors of nanoparticles were further studied. Moreover, we documented the colon targeting and pharmacodynamic properties of nanoparticles. The nanoparticles with uniform particle size exhibited pH-sensitive release, favorable gene protection, and storage stability. Cytology experiments showed that anti-miR@HCeP NPs improved the cellular uptake through HA and reduced pro-inflammatory factors. Administering anti-miR@HCeP NPs orally to IBD mice markedly reduced their pro-inflammatory factors levels and disease activity indices. We also confirmed that anti-miR@HCeP NPs mostly accumulated in the colon site, and effectively repaired the intestinal barrier, as well as relieved intestinal inflammation. The above nanoparticle is a candidate of the treatment for IBD due to its anti-inflammatory properties.
科研通智能强力驱动
Strongly Powered by AbleSci AI